Search
forLearn
5 / 801 resultslearn Beta glucan
learn nonspecific group of glycoproteins
learn oligopeptide-71
learn octapeptide-2
Research
5 / 278 results
research Establishment and characterization of five immortalized human scalp dermal papilla cell lines
Researchers created five new human scalp cell lines that could be useful for hair growth and loss research.
research Establishment and characterization of matched immortalized human frontal and occipital scalp dermal papilla cell lines from androgenetic alopecia
Scientists created cell lines from balding patients and found that cells from the front of the scalp are more affected by hormones that cause hair loss than those from the back.
research Targeted expression of SV40 T antigen in the hair follicle of transgenic mice produces an aberrant hair phenotype
SV40 T antigen in hair follicles causes abnormal hair and health issues in mice.
research Establishment of keratinocyte cell lines from human hair follicles
Scientists created keratinocyte cell lines from human hair that can differentiate similarly to normal skin cells, offering a new way to study skin biology and diseases.
research Establishment and Functional Characterization of Immortalized Rabbit Dermal Papilla Cell Lines
Researchers created a stable rabbit cell line for hair research that doesn't age quickly or become cancerous.
Community Join
5 / 1000+ resultscommunity Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community GT20029. Kintor Pharma’s Product
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.
community GT20029 - Promising phase II results
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.